Werewolf Therapeutics presents preclinical, clinical data on WTX-330
Werewolf Therapeutics (HOWL) shared clinical and preclinical data at the 2024 Society for Immunotherapy of Cancer’s 39th Annual Meeting, ...
healthandpharma2d
Overcoming Resistance in Cancer Treatment with Cytokine Therapies
We now need the next wa-ve of agents to do that. From our perspective, cytokines will be the next wave to deliver that, ...
manilatimes2d
Mural Oncology Presents Clinical and Preclinical Data Across its Pipeline at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
Preclinical data demonstrated durable immune responses and tumor growth inhibition with Mural's IL-18 variants, reinforcing ...
IMUNON Presents Positive Data from Phase 2 OVATION 2 Clinical Trial of IMNN-001 in Advanced Ovarian Cancer at SITC 39th Annual Meeting
IMNN-001 immunotherapy plus standard-of-care chemotherapy resulted in 35% improvement in overall survival and 25% improvement in progression-free survival versus standard-of-care alone Treatment was ...
Werewolf Therapeutics Presents Preclinical and Clinical Data at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting
Interim phase 1 clinical trial update reveals the clinical potential of the tumor-activated IL-12 prodrug WTX-330, with favorable tolerability ...
News Medical3d
Anti-inflammatory cytokine linked to capillary obstruction and cognitive decline in diabetes
Elevated IL-10 in diabetes causes capillary obstruction, linked to cognitive deficits. Blocking IL-10 receptors shows promise for improving brain function.
TMCnet3d
Sonnet BioTherapeutics Announces Issuance of U.S. Patent Covering a Variant IL-18 Incorporated into Two Novel Immunotherapeutic Drug Candidates
IL-18 has significant importance for cancer immune-oncology and combination with IL-12 on Sonnet’s FHAB platform which Sonnet believes could present an important oncology possibility The lock-and-load ...